U.S., Aug. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07148297) titled 'Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD' on Aug. 22.
Brief Summary: CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, for the detection of colorectal cancer. Epiliquid also integrates a proprietary bioinformatic system capable of identifying, ranking, and selecting tumor-specific methylation biomarkers for different cancer types. In this study, colorectal cancer-specific biomarkers will be evaluated in blood and tissue samples ...